Benitec (BNTC) director Sharon Mates awarded 31,500 stock options at $12.83

Rhea-AI Filing Summary

Benitec Biopharma Inc. director Sharon Mates received a grant of stock options covering 31,500 shares of common stock. The options were awarded on January 22, 2026 at an exercise price of $12.83 per share, with no cash paid at grant.

These options are held directly and give the right to buy Benitec common stock in the future. According to the terms, the options will vest on the earlier of the company’s next annual stockholders’ meeting or December 1, 2026, tying the award to a medium-term service period on the board.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mates Sharon

(Last) (First) (Middle)

C/O BENITEC BIOPHARMA INC.

3940 TRUST WAY

(Street)

HAYWARD CA 94545

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Benitec Biopharma Inc. [ BNTC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/22/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Options (right to buy)	$12.83	01/22/2026		A		31,500		(1)	01/22/2036	Common Stock	31,500	$0	31,500	D

Explanation of Responses:

1. The stock options will vest on the earlier of the Issuer's next annual stockholders' meeting or December 1, 2026.

	/s/ Sharon Mates	01/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Benitec Biopharma (BNTC) report for Sharon Mates?

Benitec Biopharma reported that director Sharon Mates was granted options to purchase 31,500 shares of common stock on January 22, 2026.

What is the exercise price of the new stock options granted to the Benitec (BNTC) director?

The options granted to director Sharon Mates have an exercise price of $12.83 per share for Benitec Biopharma common stock.

When do Sharon Mates’ Benitec (BNTC) stock options vest?

The stock options will vest on the earlier of Benitec Biopharma’s next annual stockholders’ meeting or December 1, 2026.

How many Benitec (BNTC) options does Sharon Mates hold after this transaction?

After this grant, director Sharon Mates beneficially owns 31,500 stock options for Benitec Biopharma common stock.

Is the Benitec (BNTC) option grant to Sharon Mates a direct holding?

Yes. The Form 4 indicates that the 31,500 stock options are held under direct (D) ownership by Sharon Mates.

What type of security was involved in the Benitec (BNTC) Form 4 filing?

The Form 4 reports a grant of options (right to buy) Benitec Biopharma common stock, not an immediate purchase or sale of shares.